← Leaderboards
Carlos M Ferrario
Wake Forest University
$10,416,810
Attributed
$10,416,810
Total exposure
14
Grants
9
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $2.7M · FY2005–22$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
Funding mix
By agency
NIH$45,225,427 · 15
By mechanism
P01$42,579,379 · 9
R01$1,390,009 · 2
T32$752,189 · 1
R21$426,250 · 1
M01$77,600 · 2
Top collaborators
No co-investigators on record.
Most similar at Wake Forest University
Same institution · by research overlap
- Kathleen Bridget Brosnihan$6,775,445
- Mark C Chappell$5,789,698
- Mary G Sorci-Thomas$15,439,227
- Elisabeth Ann Tallant$3,392,401
Others in their field
Top investigators on “Hypertension”
- Chanza Baytop · Westat, Inc.$271,217,917
- Paula Darby Lipman · Westat, Inc.$52,914,492
- Walter N Kernan · Yale University$42,197,025
- Rohit Varma · University Of Southern California$35,266,606
- Susan S Redline · Brigham And Women'S Hospital$35,248,244
- Marlene Rabinovitch · Stanford University$34,807,202
Research focus
HypertensionAngiotensinsAngiotensinogenBaseHeartCardiacTissuesRenin-Angiotensin SystemReninReceptorRattusPathway InteractionsResearch PersonnelReportingAntihypertensive AgentsPeptidesCardiovascular SystemAngiotensin IiPhysiologyCardiac MyocytesGenerationsCellsBiostatistics CoreLaboratories
Grant awards (69)
Angiotensin (1-12) and Hypertension in the Elderly$193,750
R21 · FY2022 · AG · contact PI
Angiotensin (1-12) and Hypertension in the Elderly$232,500
R21 · FY2021 · AG · contact PI
Vaso-Hormonal Mechanisms in Hypertension$1,682,622
P01 · FY2019 · HL · contact PI
Administrative and Biostatistical Core$359,980
P01 · FY2019 · HL · contact PI
Angiotensin-(1-12). Novel Pathways for Angiotensin Peptide Formation$119,025
P01 · FY2019 · HL · contact PI
Vaso-Hormonal Mechanisms in Hypertension$1,732,726
P01 · FY2018 · HL · contact PI
Administrative and Biostatistical Core$375,650
P01 · FY2018 · HL · contact PI
Angiotensin-(1-12). Novel Pathways for Angiotensin Peptide Formation$144,369
P01 · FY2018 · HL · contact PI
Vaso-Hormonal Mechanisms in Hypertension$1,741,868
P01 · FY2017 · HL · contact PI
Administrative and Biostatistical Core$363,852
P01 · FY2017 · HL · contact PI
Angiotensin-(1-12). Novel Pathways for Angiotensin Peptide Formation$133,664
P01 · FY2017 · HL · contact PI
Vaso-Hormonal Mechanisms in Hypertension$95,713
P01 · FY2017 · HL · contact PI
Vaso-Hormonal Mechanisms in Hypertension$1,706,717
P01 · FY2016 · HL · contact PI
Administrative and Biostatistical Core$358,307
P01 · FY2016 · HL · contact PI
Angiotensin-(1-12). Novel Pathways for Angiotensin Peptide Formation$125,324
P01 · FY2016 · HL · contact PI
Vaso-Hormonal Mechanisms in Hypertension$1,744,692
P01 · FY2015 · HL · contact PI
Administrative and Biostatistical Core$358,307
P01 · FY2015 · HL · contact PI
Angiotensin-(1-12). Novel Pathways for Angiotensin Peptide Formation$129,974
P01 · FY2015 · HL · contact PI
Vasodepressor Mechanisms in Hypertension$1,756,403
P01 · FY2013 · HL · contact PI
Angiotensin-(1 -12). Novel Pathways for Angiotensin Peptide Formation$343,495
P01 · FY2013 · HL · contact PI
Administration and Biostatistics Core$146,991
P01 · FY2013 · HL · contact PI
Vasodepressor Mechanisms in Hypertension$1,913,698
P01 · FY2012 · HL · contact PI
Angiotensin-(1 -12). Novel Pathways for Angiotensin Peptide Formation$374,142
P01 · FY2012 · HL · contact PI
Administration and Biostatistics Core$168,221
P01 · FY2012 · HL · contact PI
Vasodepressor Mechanisms in Hypertension$1,832,439
P01 · FY2011 · HL · contact PI
Angiotensin-(1 -12). Novel Pathways for Angiotensin Peptide Formation$369,146
P01 · FY2011 · HL · contact PI
Administration and Biostatistics Core$165,975
P01 · FY2011 · HL · contact PI
Vasodepressor Mechanisms in Hypertension$69,311
P01 · FY2011 · HL · contact PI
Vasodepressor Mechanisms in Hypertension$26,224
P01 · FY2011 · HL · contact PI
Vasodepressor Mechanisms in Hypertension$1,832,439
P01 · FY2010 · HL · contact PI
Angiotensin-(1 -12). Novel Pathways for Angiotensin Peptide Formation$350,852
P01 · FY2010 · HL · contact PI
Administration and Biostatistics Core$157,751
P01 · FY2010 · HL · contact PI
Vasodepressor Mechanisms in Hypertension$1,832,439
P01 · FY2009 · HL · contact PI
Angiotensin-(1-7). Novel Pathways for Angiotensin Peptide Formation$350,852
P01 · FY2009 · HL · contact PI
Administration and Biostatistics Core$157,750
P01 · FY2009 · HL · contact PI
VASODEPRESSOR MECHANISMS IN HYPERTENSION$2,140,651
P01 · FY2008 · HL · contact PI
Ang-(1-7), ACE2 and Cardiac Function$332,920
P01 · FY2008 · HL · contact PI
Core A--Administration and Biostatistics Core$186,204
P01 · FY2008 · HL · contact PI
VASODEPRESSOR MECHANISMS IN HYPERTENSION$2,188,465
P01 · FY2007 · HL · contact PI
Ang-(1-7), ACE2 and Cardiac Function$337,175
P01 · FY2007 · HL · contact PI
Core A--Administration and Biostatistics Core$222,732
P01 · FY2007 · HL · contact PI
VASODEPRESSOR MECHANISMS IN HYPERTENSION$2,203,978
P01 · FY2006 · HL · contact PI
Ang-(1-7), ACE2 and Cardiac Function$235,005
P01 · FY2006 · HL · contact PI
Core A--Administration and Biostatistics Core$166,914
P01 · FY2006 · HL · contact PI
VASODEPRESSOR MECHANISMS IN HYPERTENSION$2,128,418
P01 · FY2005 · HL
Ang-(1-7), ACE2 and Cardiac Function$230,221
P01 · FY2005 · HL
Core A--Administration and Biostatistics Core$174,767
P01 · FY2005 · HL
VASODEPRESSOR MECHANISMS IN HYPERTENSION$39,399
P01 · FY2005 · HL
VASODEPRESSOR MECHANISMS IN HYPERTENSION$28,470
P01 · FY2005 · HL
VASODEPRESSOR MECHANISMS IN HYPERTENSION$2,063,490
P01 · FY2004 · HL
ATHEROGENESIS AND THE BONE MARROW ANGIOTENSIN SYSTEM$252,000
R01 · FY2004 · HL
Ang-(1-7), ACE2 and Cardiac Function$224,004
P01 · FY2004 · HL
Core A--Administration and Biostatistics Core$164,103
P01 · FY2004 · HL
VASODEPRESSOR MECHANISMS IN HYPERTENSION$1,550,259
P01 · FY2003 · HL
ATHEROGENESIS AND THE BONE MARROW ANGIOTENSIN SYSTEM$252,000
R01 · FY2003 · HL
VASODEPRESSOR MECHANISMS IN HYPERTENSION$1,510,983
P01 · FY2002 · HL
ATHEROGENESIS AND THE BONE MARROW ANGIOTENSIN SYSTEM$324,000
R01 · FY2002 · HL
VASODEPRESSOR MECHANISMS MEDIATED BY ANGIOTENSIN (1-7)$131,864
P01 · FY2002 · HL
USE OF SERUM CONTRAST MEDIA LEVELS TO PREDICT CONTRAST NEPHROPATHY$0
M01 · FY2002 · RR
VASODEPRESSOR MECHANISMS IN HYPERTENSION$1,513,503
P01 · FY2001 · HL
ATHEROGENESIS AND THE BONE MARROW ANGIOTENSIN SYSTEM$325,125
R01 · FY2001 · HL
PATHOBIOLOGY OF VASCULAR DISEASE$317,765
T32 · FY2001 · HL
VASODEPRESSOR MECHANISMS MEDIATED BY ANGIOTENSIN (1-7)$131,864
P01 · FY2001 · HL
VASODEPRESSOR MECHANISMS IN HYPERTENSION$1,473,710
P01 · FY2000 · HL
PATHOBIOLOGY OF VASCULAR DISEASE$434,424
T32 · FY2000 · HL
ANGIOTENSIN 1-7 IN THE SPONTANEOUSLY HYPERTENSIVE$236,884
R01 · FY2000 · HL
VASODEPRESSOR MECHANISMS MEDIATED BY ANGIOTENSIN (1-7)$179,362
P01 · FY2000 · HL
USE OF SERUM CONTRAST MEDIA LEVELS TO PREDICT CONTRAST NEPHROPATHY$38,800
M01 · FY2000 · RR
BLOOD PRESSURE LOWERING MECHANISMS OF ANGIOTENSIN CONVERTING ENZYME$38,800
M01 · FY2000 · RR